(Q40536814)

21 September 2017

1 reference

title

Should poor risk patients with Hodgkin's disease be sorted out for intensive treatments? (English)

1 reference

21 September 2017

Carde P

1

1 reference

21 September 2017

publication date

1 January 1995

1 reference

21 September 2017

1 reference

21 September 2017

volume

15 Suppl 1

1 reference

21 September 2017

page(s)

31-40

1 reference

Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD

21 September 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F10428199509052703

The evolution and summary results of the Stanford randomized clinical trials of the management of Hodgkin's disease: 1962-1984.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199509052703

Measurement of drug dosage intensity in MVPP therapy in Hodgkin's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199509052703

Prognostic factors for Stage IV Hodgkin's disease treated with MOPP, with or without bleomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199509052703

Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199509052703

Relationship of histological subtypes to prognosis in early stage Hodgkin's disease: a review of 312 cases in a controlled clinical trial. The Groupe Pierre et Marie Curie.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199509052703

ChlVPP combination chemotherapy for Hodgkin's disease: long-term results

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199509052703

10.3109/10428199509052703

21 January 2018

Identifiers

DOI

1 reference

21 September 2017

1 reference